Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of E6742 in SLE Patients
NCT05278663Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of e6742 in systemic lupus erythematosus (SLE), sponsored by Eisai Co., Ltd.. Started Apr 2022; status: completed.
02
Drugs
e6742
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05278663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278663.